Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma.
Boyle EM, Proszek PZ, Kaiser MF, Begum D, Dahir N, Savola S, Wardell CP, Leleu X, Ross FM, Chiecchio L, Cook G, Drayson MT, Owen RG, Ashcroft JM, Jackson GH, Anthony Child J, Davies FE, Walker BA, Morgan GJ. Boyle EM, et al. Among authors: wardell cp. Genes Chromosomes Cancer. 2015 Feb;54(2):91-8. doi: 10.1002/gcc.22222. Epub 2014 Oct 7. Genes Chromosomes Cancer. 2015. PMID: 25287954 Free PMC article.
A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.
Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group. Boyd KD, et al. Among authors: wardell cp. Leukemia. 2012 Feb;26(2):349-55. doi: 10.1038/leu.2011.204. Epub 2011 Aug 12. Leukemia. 2012. PMID: 21836613 Free PMC article.
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gonzalez D, Walker BA, Hockley SL, Wardell CP, Gregory WM, Child JA, Jackson GH, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group. Boyd KD, et al. Among authors: wardell cp. Genes Chromosomes Cancer. 2011 Oct;50(10):765-74. doi: 10.1002/gcc.20899. Genes Chromosomes Cancer. 2011. PMID: 21961181 Clinical Trial.
Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.
Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, Kaiser MF, Walker BA, Begum DB, Dahir NB, Proszek P, Gregory WM, Drayson MT, Jackson GH, Ross FM, Davies FE, Morgan GJ. Pawlyn C, et al. Among authors: wardell cp. Blood. 2015 Jan 29;125(5):831-40. doi: 10.1182/blood-2014-07-584268. Epub 2014 Nov 26. Blood. 2015. PMID: 25428216 Free PMC article. Clinical Trial.
Improved risk stratification in myeloma using a microRNA-based classifier.
Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ. Wu P, et al. Br J Haematol. 2013 Aug;162(3):348-59. doi: 10.1111/bjh.12394. Epub 2013 May 30. Br J Haematol. 2013. PMID: 23718138 Free article.
MMSET is the key molecular target in t(4;14) myeloma.
Mirabella F, Wu P, Wardell CP, Kaiser MF, Walker BA, Johnson DC, Morgan GJ. Mirabella F, et al. Among authors: wardell cp. Blood Cancer J. 2013 May 3;3(5):e114. doi: 10.1038/bcj.2013.9. Blood Cancer J. 2013. PMID: 23645128 Free PMC article. No abstract available.
Gender disparities in the tumor genetics and clinical outcome of multiple myeloma.
Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Davies FE, Morgan GJ. Boyd KD, et al. Among authors: wardell cp. Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1703-7. doi: 10.1158/1055-9965.EPI-11-0157. Epub 2011 Jun 15. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21680536 Free PMC article. Clinical Trial.
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.
Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gregory WM, Jackson GH, Child JA, Davies FE, Morgan GJ; NCRI Haematology Oncology Studies Group. Boyd KD, et al. Among authors: wardell cp. Clin Cancer Res. 2011 Dec 15;17(24):7776-84. doi: 10.1158/1078-0432.CCR-11-1791. Epub 2011 Oct 12. Clin Cancer Res. 2011. PMID: 21994415 Free PMC article.
66 results